These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29070877)

  • 1. Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence.
    Thierry E; Lebourgeois S; Simon F; Delelis O; Deprez E
    Sci Rep; 2017 Oct; 7(1):14067. PubMed ID: 29070877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
    Chitongo R; Obasa AE; Mikasi SG; Jacobs GB; Cloete R
    PLoS One; 2020; 15(5):e0223464. PubMed ID: 32379830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
    DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR
    PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance.
    Munir S; Thierry E; Malet I; Subra F; Calvez V; Marcelin AG; Deprez E; Delelis O
    J Antimicrob Chemother; 2015 Mar; 70(3):739-49. PubMed ID: 25414202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes.
    Pollicita M; Surdo M; Di Santo F; Cortese MF; Fabeni L; Fedele V; Malet I; Marcelin AG; Calvez V; Ceccherini-Silberstein F; Perno CF; Svicher V
    J Antimicrob Chemother; 2014 Sep; 69(9):2412-9. PubMed ID: 24860155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.
    Johnson BC; Métifiot M; Pommier Y; Hughes SH
    Antimicrob Agents Chemother; 2012 Jan; 56(1):411-9. PubMed ID: 22037850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance.
    Malet I; Ambrosio FA; Subra F; Herrmann B; Leh H; Bouger MC; Artese A; Katlama C; Talarico C; Romeo I; Alcaro S; Costa G; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2018 May; 73(5):1158-1166. PubMed ID: 29373677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors.
    Peese KM; Naidu BN; Patel M; Li C; Langley DR; Terry B; Protack T; Gali V; Lin Z; Samanta HK; Zheng M; Jenkins S; Dicker IB; Krystal MR; Meanwell NA; Walker MA
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126784. PubMed ID: 31761656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.
    Anstett K; Cutillas V; Fusco R; Mesplède T; Wainberg MA
    J Antimicrob Chemother; 2016 Aug; 71(8):2083-8. PubMed ID: 27084918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
    Engelman AN; Cherepanov P
    FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
    Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
    Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
    Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
    Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
    Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
    mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.